Summary The arotinoid Ro 40-8757 was previously shown to inhibit the growth of a variety of human cancer cell lines derived from breast, lung and uterus. In view of the high incidence of human digestive cancers, and the slow progress in the development of new therapy, we examined in this paper several combinations between the new arotinoid Ro 40-8757, 5-fluorouracil (5FU) and interferon a-2a on the growth of nine human cancer cell lines derived from the gastrointestinal and pancreatic system. Half-maximal inhibition of cell proliferation by Ro 40-8757 was observed at concentrations ranging between 0.18 and 0.57 um, and increased up to 4.7 gM in retinoid-resistant CAPAN 620 pancreatic cells. All-trans-retinoic acid was 70 times less potent. The sensitivity of HT29-5FU-resistant colonic cells was similar to that observed in the parental cells, suggesting an action independent of pyrimidine metabolism. Ro 40-8757 did not induce any differentiation on HT29 cells, as suggested by ultrastructural analysis. The arotinoid did not interact with receptor signal transduction pathways under the control of serum components, such as growth factors as half-maximal inhibition of growth was similar in HT29-S-B6 cells cultured in the absence or presence of serum. Cell cycle analysis showed that Ro 40-8757 was not acting at a phase-specific transition in HT29 cells and, accordingly, did not induce overexpression of the protein kinase C (PKC)a isoform, or conversion of hyperphosphorylated p105 Rb into hypophosphorylated forms. However, the arotinoid induced significant accumulation of the dephosphorylated, active form of the tumour-suppressor protein. Combinations of Ro 40-8757 with 5FU and interferon a2a resulted in an additive but not synergistic antiproliferative action in HT29 cells. Our data support the interest in Ro 40-8757 as a potent anti-cancer drug, especially in combination therapy with 5FU and interferon, in gastrointestinal and pancreatic cancers, where new active therapeutic modalities are urgently needed.
The retinoids, including vitamin A and its metabolites, and synthetic derivatives are very potent drugs affecting cellular proliferation and differentiation (Hong and Itri, 1994) . Thus, retinoids have been reported to be active in several skin diseases such as actinic keratosis (Moriarty et al., 1982) , oral leucoplakia (Hong et al., 1986 ) and xeroderma pigmentosum (Kraemer et al., 1988) . They were also shown to induce differentiation and to inhibit cell growth in various types of cancers both in vitro and in vivo (Lippman et al., 1987a,b) . Preclincial studies have led to the development of first-and second-generation retinoids, used alone or in combination with cytotoxic drugs, in the treatment of acute promyelocytic leukaemia (Castaigne et al., 1990; Degos et al., 1995) , advanced squamous cell carcinoma of the cervix , skin cancer (Meyskens et al., 1985) or in the prevention of second primary cancers in head and neck carcinoma patients . In an attempt to find new indications of retinoids in cancer therapy, many derivatives have been synthesised. Among these, the thirdgeneration retinoids, the arotinoids, are of particular interest. Thus, temarotene (Ro 15-0778) induces regression of established mammary carcinomas in the rat, without sideeffects that are usually associated with hypervitaminosis A (Teelman et al., 1988) . The most active compound identified among these third-generation retinoids is Ro 40-8757 mofarotene; 4-[2-[p-[-(E)-2(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl) propenyl]ethyl]morpholine]. This compound is more active than a series of other retinoids tested in rat mammary cancer (Teelman et al., 1993) . It inhibits the growth of various human cancer cell lines in vitro and, moreover, protects the bone marrow from the toxic effects of cyclophosphamide and 5-fluorouracil (5FU) in vivo . In this context, we found that Ro 40-8757 was the most effective antiproliferative retinoid, out of 13 compounds tested in a preliminary screening using the human colon cancer HT29 cell line (Zimber et al., 1993) . This arotinoid was also recently reported to inhibit oral carcinogenesis in male F344 rats (Tanaka et al., 1995) . In the present work, we have analysed the antiproliferative effects of Ro 40-8757 in nine human cancer cell lines originating from the colon, stomach and pancreas. Cell cycle distribution and expression of the Rbl retinoblastoma and protein kinase C (PKC)cL mRNA and proteins, which are involved in cell proliferation and differentiation (Delage et al., 1993; Buchovich et al., 1989) , were studied in HT29 cells exposed to Ro 40-8757. Ultrastructural analysis of HT29 cells exposed or not to Ro 40-8757 was performed, and did not show any differentiating effect of this arotinoid. In addition, we tested the inhibition of HT29 cell growth by Ro 40-8757 alone or combined with 5FU or interferon a2a (IFN-a2a): combination of retinoids and interferon was strongly recommended as additive and synergistic effects between the two drugs have been observed in various preclinical and clinical situations (Bollag et al., 1994; Toma et al., 1994) . Combination of Ro 40-8757 and 5FU, the most commonly used drug in gastrointestinal tumour therapy, was performed in an attempt to eliminate the possibility of any drug antagonistic effect in this combination.
Cancer Research, NY, USA). The HT29-S-B6 cell line is a subclone obtained in our laboratory from the parental HT29 cells after serum deprivation ; the HT29-5FU cell line was obtained from Dr A Zweibaum (INSERM U178, Villejuif, France). It was selected from the parental HT29 cells after progressive adaptation to 5FU (Lesuffleur et al., 1991a) . In this cell line, resistance to 5FU was acquired through thymidylate synthase gene amplification (Lesuffleur et al., 1991b .
Northern blot analysis HT29 cells were washed twice with ice-cold phosphatebuffered saline (PBS) and then scraped in 4 M guanidinium isothiocyanate containing 25 mm sodium citrate, 0.1 M 2-mercaptoethanol, 0.5% sarkosyl at pH 7.0. RNA was isolated by centrifugation through a cushion of 5.7 M caesium chloride (Chirgwin et al., 1979) . RNA samples containing 20 Mg of total RNA were electrophoresed through 0.8% agarose-6% formaldehyde gels and blotted onto Hybond-N nylon membranes in 20 x SSC (1 x SSC corresponds to 0.15 M sodium chloride plus 15 mm sodium citrate). The membranes were hybridised for 12 h at 42°C to random-primed 32P-labelled probes. The Rbl probe was the human cDNA isolated from the pCVM-HRB plasmid, kindly provided by Dr R Weinberg (Cambridge, USA). The PKCax probe was the 1294 bp fragment of the human cDNA, isolated after EcoRI digestion from the phPKC-cx7 plasmid, kindly provided by Dr N M Sposi. After hybridisation, blots were washed at high stringency (0.1 x SSC, 0.1% sodium dodecyl sulphate (SDS) at 57°C) and autoradiographed. Ribosomal RNA was used as a reference for homogeneity of loading, and molecular weight markers were included.
Western blot analysis Total cellular extracts were prepared in sample buffer containing 8 M urea, 5% SDS, 5% 2-mercaptoethanol, 10% glycerol, 0.02% bromophenol blue, Tris-base (pH 6.8).
Aliquots of 25 Mg of protein were electrophoresed through SDS-polyacrylamide gel containing 6-7.5% acrylamide and 0.1% SDS. Proteins were transferred to nitrocellulose filter membranes (Bio-Rad Laboratories, Richmond, CA). The membranes were briefly stained with Ponceau S to mark the position of molecular weight standards and to assess equal transfer of proteins, then blocked for 1 h at 37°C with 3% bovine serum albumin (BSA) and 0.05% Nonidet in Trissodium chloride buffer (50 mM Tris-base, 150 mM sodium chloride, pH 7.6)) and incubated for 1 h at room temperature with the appropriate antibodies. The rabbit anti-Rbl PAb C15 from Santa Cruz Biotechnology (Tebu, France) was used at a 1:100 dilution. The PKCoc specific antibody (Blobe GC, 1993) was a gift from Dr Y Hannun (Durham, NC, USA). The immunoblots were then washed in Tris-saline buffer, incubated for 1 h at 22°C with a 1:1000 dilution of polyclonal sheep anti-rabbit immunoglobulin antibody conjugated with horseradish peroxidase, and probed using the enhanced chemiluminescence system (ECL, Amersham, UK).
Electron microscopy HT29 cells treated for 12 days with Ro 40-8757 at the concentration of 3 x 10-5 M were processed for transmission electron microscopy, as described previously (Chastre et al., 1993) .
Statistical evaluation
Results of cell proliferation data are expressed as means + s.d. of at least three independent experiments using two determinations for each cell count. Differences between means were analysed using Student's t-test, with P < 0.05 being considered statistically significant.
Results
Inhibition of cell proliferation by Inhibition of tumour cell proliferation by Ro 40-8757 was observed in a dose-dependent manner in all the cell lines examined, as shown in Figure 1 .
The membrane-bound activated PKC is also involved in the regulation of cell proliferation, and PKCa is a major isoform detected in colonic epithelial cells (Nishizuka, 1986 (Figure 4 ). When the three drugs were combined at concentrations corresponding to their half-maximal inhibitory effects, more than 80% inhibition was observed (Figure 4 ).
Discussion
New therapeutic agents and strategies are expected in the treatment of gastrointestinal and pancreatic cancers when . In this report, we demonstrate that this new drug also exerts remarkable antiproliferative effects in human cancer cell lines derived from the digestive tract, without inducing differentiation in the parental HT29 colonic cell line. However, clinical trials are needed before drawing any conclusion as in vitro chemosensitivity studies are not always predictive of in vivo activity. Moreover, drug exposure at the concentrations used in this study could perhaps not be obtained in vivo without significant toxicity. The mechanism of action of the arotinoid Ro 40-8757 is not yet known. Although the structure of Ro 40-8757 is related to retinoic acid, it differs from classical retinoids (alltrans and 13-cis) as it does not bind to any of nuclear retinoic acid receptors identified so far (RAR-oc, -fi, -y, RXR-cx -fi, -,y), and it does not regulate retinoic acid response element (RARE)-dependent transcription . Moreover, it does not reproduce the all-trans retinoic acidinduced granulocytic differentiation in HL60 human promyelocytes ). An antiproliferative effect in human breast cancer cells of another synthetic retinoid (AHPN), which is also independent of RAR or RXR binding, was recently reported (Shao et al., 1995) . Ro 40-8757 could act through other retinoid receptors, recently described as 'orphan receptors' (Mangelsdorf and Evans, 1995) . Previous reports on the effects of classical retinoic acids in gastrointestinal malignancies were disappointing (Hong et al., 1994) . In the present study, all-trans retinoic acid was about 70 times less potent than Ro 40-8757 in producing the same antiproliferative effect in HT29 cells.
Our data demonstrate that Ro 40-8757 does not induce any phase-specific blockade in the HT29 cell cycle, as reported for two human breast cancer cell lines (Eliason et al., 1994b) . Several target sites and metabolic effects might be involved in the antiproliferative action of this compound. Some other cytostatic drugs, such as nitrosoureas or bleomycin, are also non-cell cycle phase specific (Skeel et al., 1995) , and this hypothesis is sustained by our data on the Rbl status in HT29 cells exposed to this retinoid. Hypophosphorylated forms of plO5Rb are known to inhibit cell proliferation at the GI phase of the cell cycle through physical association and sequestration of key transcription factors such as E2F, leading to inhibition of E2F-mediated transactivation (Chellapah et al., 1991) . Several genes encoding cell cycle regulators harbour promoters containing E2F binding sites that contribute to the expression of myc, cdc2 and the effectors of DNA synthesis: thymidine kinase, thymidylate synthase, dihydrofolate reductase and DNA polymerase a . Furthermore, E2F-pRb complexes dissociate before the GI/S boundary upon pRbl phosphorylation (Cao et al., 1992) . In HT29 cells, Ro 40-8757 does not induce the conversion of hyperphosphorylated Rb into hypophosphorylated p105 forms, while only hypophosphorylated Rbl was detected in freshly isolated normal human colonic epithelial crypts (Figure 4) . However, the antiproliferative action of the arotinoid may be partly explained by increased levels of hypophosphorylated plO5Rb as the amount of the active Rb form of this tumoursuppressor protein plays an important role in the regulation of oncogenic and mitogenic pathways via interactions with nuclear transcription factors or tyrosine kinases (Craven et al., 1995; Muller, 1995 
